Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: Clinical Implications and Treatment
The prevalence of nonalcoholic fatty liver disease (NAFLD) is expected to rise along with the global obesity epidemic. As NAFLD is the most common cause of chronic liver disease in the United States, it has become a major health concern. It affects all ethnicities, with the highest prevalence among...
Gespeichert in:
| Veröffentlicht in: | Nutrition in clinical practice 2013-02, Vol.28 (1), p.40-51 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 51 |
|---|---|
| container_issue | 1 |
| container_start_page | 40 |
| container_title | Nutrition in clinical practice |
| container_volume | 28 |
| creator | Rahimi, Robert S. Landaverde, Carmen |
| description | The prevalence of nonalcoholic fatty liver disease (NAFLD) is expected to rise along with the global obesity epidemic. As NAFLD is the most common cause of chronic liver disease in the United States, it has become a major health concern. It affects all ethnicities, with the highest prevalence among the Hispanic population. Individuals with nonalcoholic steatohepatitis (NASH), the more serious form of NAFLD, are at increased risk of developing cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Since NAFLD is intricately associated with the metabolic syndrome and insulin resistance, increased risk of cardiovascular disease and mortality become a real concern. It has recently been shown that current nutrition trends, such as increased consumption of high-fructose corn syrup and certain types of fats, may have an important role in the increased NAFLD prevalence. As there are no ideal treatment options available for NAFLD, a multifaceted treatment approach should be tailored to each individual patient. |
| doi_str_mv | 10.1177/0884533612470464 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273544518</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0884533612470464</sage_id><sourcerecordid>1273544518</sourcerecordid><originalsourceid>FETCH-LOGICAL-c290t-44a5cd9797936bd46d57663e874e072dee7cc0bbb4fd8dfb28f04fdbb7bd1b7d3</originalsourceid><addsrcrecordid>eNp1kM1Lw0AQxRdRbK3ePUmOXqL7ld0NnqRaFaoe1HPYj4lNSbJ1NxH635va6kGQOczA-70H8xA6JfiCECkvsVI8Y0wQyiXmgu-hMck5SSnP6D4ab-R0o4_QUYxLjIliUh2iEWVUiZzKMbp68q2urV_4urLJTHfdOplXnxCSmyqCjpDo1iXdApJH6LT5pl7WrQu-gWN0UOo6wsluT9Db7PZ1ep_On-8eptfz1NIcdynnOrMul8MwYRwXLpNCMFCSA5bUAUhrsTGGl0650lBV4uE0RhpHjHRsgs63uavgP3qIXdFU0UJd6xZ8HwtCJcs4z4bvJghvURt8jAHKYhWqRod1QXCxqaz4W9lgOdul96YB92v46WgA0i0Q9TsUS9-HobH4f-AXpmxzDQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273544518</pqid></control><display><type>article</type><title>Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: Clinical Implications and Treatment</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><source>Alma/SFX Local Collection</source><creator>Rahimi, Robert S. ; Landaverde, Carmen</creator><creatorcontrib>Rahimi, Robert S. ; Landaverde, Carmen</creatorcontrib><description>The prevalence of nonalcoholic fatty liver disease (NAFLD) is expected to rise along with the global obesity epidemic. As NAFLD is the most common cause of chronic liver disease in the United States, it has become a major health concern. It affects all ethnicities, with the highest prevalence among the Hispanic population. Individuals with nonalcoholic steatohepatitis (NASH), the more serious form of NAFLD, are at increased risk of developing cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Since NAFLD is intricately associated with the metabolic syndrome and insulin resistance, increased risk of cardiovascular disease and mortality become a real concern. It has recently been shown that current nutrition trends, such as increased consumption of high-fructose corn syrup and certain types of fats, may have an important role in the increased NAFLD prevalence. As there are no ideal treatment options available for NAFLD, a multifaceted treatment approach should be tailored to each individual patient.</description><identifier>ISSN: 0884-5336</identifier><identifier>EISSN: 1941-2452</identifier><identifier>DOI: 10.1177/0884533612470464</identifier><identifier>PMID: 23286927</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Carbonated Beverages - adverse effects ; Carcinoma, Hepatocellular - complications ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - therapy ; Cardiovascular Diseases - complications ; Cardiovascular Diseases - pathology ; Cardiovascular Diseases - therapy ; Fatty Liver - complications ; Fatty Liver - epidemiology ; Fatty Liver - pathology ; Fatty Liver - therapy ; Hispanic Americans ; Humans ; Insulin Resistance ; Life Style ; Liver - pathology ; Liver Cirrhosis - complications ; Liver Cirrhosis - pathology ; Liver Cirrhosis - therapy ; Liver Neoplasms - complications ; Liver Neoplasms - pathology ; Liver Neoplasms - therapy ; Metabolic Syndrome - complications ; Metabolic Syndrome - epidemiology ; Metabolic Syndrome - pathology ; Metabolic Syndrome - therapy ; Non-alcoholic Fatty Liver Disease ; Nursing ; Obesity - complications ; Obesity - pathology ; Obesity - therapy ; Prevalence ; United States - epidemiology</subject><ispartof>Nutrition in clinical practice, 2013-02, Vol.28 (1), p.40-51</ispartof><rights>2013 American Society for Parenteral and Enteral Nutrition</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c290t-44a5cd9797936bd46d57663e874e072dee7cc0bbb4fd8dfb28f04fdbb7bd1b7d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23286927$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rahimi, Robert S.</creatorcontrib><creatorcontrib>Landaverde, Carmen</creatorcontrib><title>Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: Clinical Implications and Treatment</title><title>Nutrition in clinical practice</title><addtitle>Nutr Clin Pract</addtitle><description>The prevalence of nonalcoholic fatty liver disease (NAFLD) is expected to rise along with the global obesity epidemic. As NAFLD is the most common cause of chronic liver disease in the United States, it has become a major health concern. It affects all ethnicities, with the highest prevalence among the Hispanic population. Individuals with nonalcoholic steatohepatitis (NASH), the more serious form of NAFLD, are at increased risk of developing cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Since NAFLD is intricately associated with the metabolic syndrome and insulin resistance, increased risk of cardiovascular disease and mortality become a real concern. It has recently been shown that current nutrition trends, such as increased consumption of high-fructose corn syrup and certain types of fats, may have an important role in the increased NAFLD prevalence. As there are no ideal treatment options available for NAFLD, a multifaceted treatment approach should be tailored to each individual patient.</description><subject>Carbonated Beverages - adverse effects</subject><subject>Carcinoma, Hepatocellular - complications</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Cardiovascular Diseases - complications</subject><subject>Cardiovascular Diseases - pathology</subject><subject>Cardiovascular Diseases - therapy</subject><subject>Fatty Liver - complications</subject><subject>Fatty Liver - epidemiology</subject><subject>Fatty Liver - pathology</subject><subject>Fatty Liver - therapy</subject><subject>Hispanic Americans</subject><subject>Humans</subject><subject>Insulin Resistance</subject><subject>Life Style</subject><subject>Liver - pathology</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver Cirrhosis - therapy</subject><subject>Liver Neoplasms - complications</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - therapy</subject><subject>Metabolic Syndrome - complications</subject><subject>Metabolic Syndrome - epidemiology</subject><subject>Metabolic Syndrome - pathology</subject><subject>Metabolic Syndrome - therapy</subject><subject>Non-alcoholic Fatty Liver Disease</subject><subject>Nursing</subject><subject>Obesity - complications</subject><subject>Obesity - pathology</subject><subject>Obesity - therapy</subject><subject>Prevalence</subject><subject>United States - epidemiology</subject><issn>0884-5336</issn><issn>1941-2452</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1Lw0AQxRdRbK3ePUmOXqL7ld0NnqRaFaoe1HPYj4lNSbJ1NxH635va6kGQOczA-70H8xA6JfiCECkvsVI8Y0wQyiXmgu-hMck5SSnP6D4ab-R0o4_QUYxLjIliUh2iEWVUiZzKMbp68q2urV_4urLJTHfdOplXnxCSmyqCjpDo1iXdApJH6LT5pl7WrQu-gWN0UOo6wsluT9Db7PZ1ep_On-8eptfz1NIcdynnOrMul8MwYRwXLpNCMFCSA5bUAUhrsTGGl0650lBV4uE0RhpHjHRsgs63uavgP3qIXdFU0UJd6xZ8HwtCJcs4z4bvJghvURt8jAHKYhWqRod1QXCxqaz4W9lgOdul96YB92v46WgA0i0Q9TsUS9-HobH4f-AXpmxzDQ</recordid><startdate>201302</startdate><enddate>201302</enddate><creator>Rahimi, Robert S.</creator><creator>Landaverde, Carmen</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201302</creationdate><title>Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome</title><author>Rahimi, Robert S. ; Landaverde, Carmen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c290t-44a5cd9797936bd46d57663e874e072dee7cc0bbb4fd8dfb28f04fdbb7bd1b7d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Carbonated Beverages - adverse effects</topic><topic>Carcinoma, Hepatocellular - complications</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Cardiovascular Diseases - complications</topic><topic>Cardiovascular Diseases - pathology</topic><topic>Cardiovascular Diseases - therapy</topic><topic>Fatty Liver - complications</topic><topic>Fatty Liver - epidemiology</topic><topic>Fatty Liver - pathology</topic><topic>Fatty Liver - therapy</topic><topic>Hispanic Americans</topic><topic>Humans</topic><topic>Insulin Resistance</topic><topic>Life Style</topic><topic>Liver - pathology</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver Cirrhosis - therapy</topic><topic>Liver Neoplasms - complications</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - therapy</topic><topic>Metabolic Syndrome - complications</topic><topic>Metabolic Syndrome - epidemiology</topic><topic>Metabolic Syndrome - pathology</topic><topic>Metabolic Syndrome - therapy</topic><topic>Non-alcoholic Fatty Liver Disease</topic><topic>Nursing</topic><topic>Obesity - complications</topic><topic>Obesity - pathology</topic><topic>Obesity - therapy</topic><topic>Prevalence</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rahimi, Robert S.</creatorcontrib><creatorcontrib>Landaverde, Carmen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nutrition in clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rahimi, Robert S.</au><au>Landaverde, Carmen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: Clinical Implications and Treatment</atitle><jtitle>Nutrition in clinical practice</jtitle><addtitle>Nutr Clin Pract</addtitle><date>2013-02</date><risdate>2013</risdate><volume>28</volume><issue>1</issue><spage>40</spage><epage>51</epage><pages>40-51</pages><issn>0884-5336</issn><eissn>1941-2452</eissn><abstract>The prevalence of nonalcoholic fatty liver disease (NAFLD) is expected to rise along with the global obesity epidemic. As NAFLD is the most common cause of chronic liver disease in the United States, it has become a major health concern. It affects all ethnicities, with the highest prevalence among the Hispanic population. Individuals with nonalcoholic steatohepatitis (NASH), the more serious form of NAFLD, are at increased risk of developing cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Since NAFLD is intricately associated with the metabolic syndrome and insulin resistance, increased risk of cardiovascular disease and mortality become a real concern. It has recently been shown that current nutrition trends, such as increased consumption of high-fructose corn syrup and certain types of fats, may have an important role in the increased NAFLD prevalence. As there are no ideal treatment options available for NAFLD, a multifaceted treatment approach should be tailored to each individual patient.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>23286927</pmid><doi>10.1177/0884533612470464</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0884-5336 |
| ispartof | Nutrition in clinical practice, 2013-02, Vol.28 (1), p.40-51 |
| issn | 0884-5336 1941-2452 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1273544518 |
| source | MEDLINE; Wiley Online Library All Journals; Alma/SFX Local Collection |
| subjects | Carbonated Beverages - adverse effects Carcinoma, Hepatocellular - complications Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy Cardiovascular Diseases - complications Cardiovascular Diseases - pathology Cardiovascular Diseases - therapy Fatty Liver - complications Fatty Liver - epidemiology Fatty Liver - pathology Fatty Liver - therapy Hispanic Americans Humans Insulin Resistance Life Style Liver - pathology Liver Cirrhosis - complications Liver Cirrhosis - pathology Liver Cirrhosis - therapy Liver Neoplasms - complications Liver Neoplasms - pathology Liver Neoplasms - therapy Metabolic Syndrome - complications Metabolic Syndrome - epidemiology Metabolic Syndrome - pathology Metabolic Syndrome - therapy Non-alcoholic Fatty Liver Disease Nursing Obesity - complications Obesity - pathology Obesity - therapy Prevalence United States - epidemiology |
| title | Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: Clinical Implications and Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T20%3A49%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nonalcoholic%20Fatty%20Liver%20Disease%20and%20the%20Metabolic%20Syndrome:%20Clinical%20Implications%20and%20Treatment&rft.jtitle=Nutrition%20in%20clinical%20practice&rft.au=Rahimi,%20Robert%20S.&rft.date=2013-02&rft.volume=28&rft.issue=1&rft.spage=40&rft.epage=51&rft.pages=40-51&rft.issn=0884-5336&rft.eissn=1941-2452&rft_id=info:doi/10.1177/0884533612470464&rft_dat=%3Cproquest_cross%3E1273544518%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273544518&rft_id=info:pmid/23286927&rft_sage_id=10.1177_0884533612470464&rfr_iscdi=true |